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Abstract
Introduction: Advanced ovarian cancer surgery (AOCS) frequently results in serious postoperative complications.
Because managing AOCS is difficult, some standards need to be established that allow surgeons to assess the
quality of treatment provided and consider what aspects should improve. This study aimed to identify quality
indicators (QIs) of clinical relevance and to establish their acceptable quality limits (i.e., standard) in AOCS.
Materials and methods: We performed a systematic search on clinical practice guidelines, consensus conferences,
and reviews on the outcome and quality of AOCS to identify which QIs have clinical relevance in AOCS. We then
searched the literature (from January 2006 to December 2018) for each QI in combination with the keywords of
advanced ovarian cancer, surgery, outcome, and oncology. Standards for each QI were determined by statistical
process control techniques. The acceptable quality limits for each QI were defined as being within the limits of the
99.8% interval, which indicated a favorable outcome.
Results: A total of 38 studies were included. The QIs selected for AOCS were complete removal of the tumor upon
visual inspection (complete cytoreductive surgery), a residual tumor of < 1 cm (optimal cytoreductive surgery), a
residual tumor of > 1 cm (suboptimal cytoreductive surgery), major morbidity, and 5-year survival. The rates of
complete cytoreductive surgery, optimal cytoreductive surgery, suboptimal cytoreductive surgery, morbidity, and 5-
year survival had quality limits of < 27%, < 23%, > 39%, > 33%, and < 27%, respectively.
Conclusion: Our results provide a general view of clinical indicators for AOCS. Acceptable quality limits that can be
considered as standards were established.
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Highlights
 Quality indicators are described in advanced ovarian
cancer surgery(AOCS)
 Acceptable quality limits are defined as standards in
AOCS
Introduction
Advanced ovarian cancer surgery (AOCS) aims to
achieve maximal cytoreduction to increase survival, and
even provide a definitive cure in some cases. Generally,
this comprises an aggressive surgery that frequently re-
sults in serious postoperative complications, including
patient’s mortality or the impossibility of administration
of subsequent oncological treatments. These complica-
tions can directly affect survival [1, 2].
A standard defines the range in which the level of
quality reached in a certain process is acceptable, leading
to establishment of the minimum allowable for an
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indicator. This implies comparing results in manage-
ment of a specific disease through measurable, valid, and
relevant indicators [3]. Because of the difficulty in man-
aging advanced ovarian cancer (AOC), some standards
need to be established that allow surgeons to assess the
quality of the treatment provided and consider what as-
pects should improve, as well as compare their results
with those of other groups. Investigation of quality surgi-
cal care is a multidimensional and complex challenge.
The concept of quality may reflect different aspects of
medical care, depending on the perspective under con-
sideration. Structure (e.g., sufficient personnel, resuscita-
tion cart availability, and working atmosphere), process
(e.g., percentage of patients fulfilling the antibiotic
prophylaxis protocol and patients with informed con-
sent), and direct clinical outcomes (e.g., morbidity, mor-
tality, and wound dehiscence) can be measured as a
reflection of the quality of medical care [4].
Because of the complexity of AOCS, clinicians and
surgeons require additional quality indicators (QIs) and
their variability limits to determine what may be consid-
ered optimal or suboptimal treatment. This study aimed
to identify QIs of clinical relevance and to establish their




The research process was carried out in two parts. First,
we needed to identify which QIs have clinical relevance
in AOCS. Therefore, we performed a systematic search
on clinical practice guidelines [5–7], consensus confer-
ences [8], and reviews on the outcomes and quality of
AOCS [9–15] that were published in MEDLINE/
PubMed, Embase, and the Cochrane Library.
Second, once a series of QIs were selected from this
literature, a new search was performed for each QI in
combination with the Medical Subject Heading key-
words of advanced ovarian cancer, ovary, surgery, and
oncology. Only papers published from January 2006 to
December 2018 were included in this part of the investi-
gation. Additional relevant studies were also selected
from the references that were obtained through the
search. For inclusion in the analysis, each evaluated QI
had to be clearly mentioned in the text or be easily cal-
culated from the data presented in the study. When
studies included series with oncological and non-
oncological cases, careful selection of the results of the
oncological cases was performed. When such selection
was not possible, the paper was not included. When sev-
eral studies were reported by the same institution, the
study with the highest number of cases was selected.
When studies included results from primary cytoreduc-
tive surgery and interval debulking surgery, careful
selection of the primary cytoreductive surgery results
was made. Studies were not included when such selec-
tion could not be performed. Despite being a retrospect-
ive review study of data from other authors, informed
consent for the analysis was obtained from the Ethics
and Research Committee (No. 02223/2019)
Selection of QIs and studies
Indicators were selected according to clinical relevance
(factors that clearly affected the prognosis or the postop-
erative course) and frequency of appearance in the dif-
ferent studies to ensure a sufficient amount of data for
evaluation. Each QI was investigated individually. There-
fore, there were different numbers of studies and cases
for each QI, depending on the information available for
each item in particular. Publications were only included
in our study if they presented a minimum number of 50
cases for each item. Series that reported national or col-
lected databases with thousands of patients were ex-
cluded because these studies did not clearly reflect the
results of any particular team or institution.
Data collection and determination of standards
Standards for each QI were determined by statistical
process control (SPC) techniques. P-charts (categorical
data) and X-charts (continuous data) were plotted to
graphically represent the weighted average according to
sample size as a quality standard. The studies were
sorted in the charts according to the number of cases in-
cluded in each series from a smaller to a larger volume
of patients. According to Spiegelhalter et al. [16, 17] two
limits represented by 99.8% confidence intervals (±3
standard deviations [SDs]) and 95% confidence intervals
(±2 SDs) are calculated from the weighted average to es-
tablish variability limits. Any result outside of these
limits significantly deviates from the weighted average (p
< 0.002 and p < 0.05, respectively), and is considered out
of control according to the SPC terminology. In our
study, the AQLs for each QI were defined as being
within the limits of the 99.8% interval, which indicated a
favorable outcome. When a result was within the AQLs,
it was considered to be within the standards.
Results
QIs
The QIs selected for AOCS were complete removal of
the tumor upon visual inspection (complete cytoreduc-
tive surgery [CCS]), a residual tumor of < 1 cm (optimal
cytoreductive surgery [OCS]), a residual tumor of > 1
cm (suboptimal cytoreductive surgery [SCS]) [2], major
morbidity (grades III and IV of Clavien–Dindo classifica-
tion) [18], and 5-year survival. A total of 38 studies were
identified (Table 1) [19–54].
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Cytoreductive rate
The CCS rate was evaluated in 28 series with a total of
7450 patients included. The weighted average CCS was
38% and the quality limit was < 27% (Fig. 1).
The OCS rate was evaluated in 26 series with a
total of 6933 patients included. The weighted aver-
age OCS was 33% and the quality limit was < 23%
(Fig. 2).
Table 1 Primary cytoreductive surgery results in advanced ovarian cancer
Author N CCS % CCS Nº OCS % OCS Nº SCS % SCS Nº Major complications % 5 Year survival %
Du Bois et al. 2009 [19] 3126 33.5 1046 31.2 975 35.3 1105 39
Bookman et al. 2009 [20] 4312 24.2 1044 45.1 1949 30.5 1319
Chang et al. 2012 [21] 203 31 63 38 77 31 63 38 50
Chi et al. 2012 [22] 285 24 69 47 134 29 82 10
Colombo et al. 2008 [23] 142 25.6 39 35.2 50 37.3 53 14 30
Fago-Olsen et al. 2014 [24] 990 39 381 27 266 35 341 19 30
Fagotti et al. 2013 [25] 148 62 92 27.7 41 10 15 8 30
Luyckx et al. 2012 [26] 527 71 374 18 94 11 57 50
Peiretti et al. 2010 [27] 288 44 115 32 83 24 61 16 49
Rauh-Hain et al. 2012 [28] 176 7.5 13 58 102 34 61 30 20
Rauh-Hain et al. 2013 [29] 330 26 85 56 187 17.6 58
Rosen et al. 2014 [30] 143 41.5 76 22.4 41 35.5 65 50
Sehouli et al. 2010 [31] 332 59.8 196 27.4 90 12.5 41 36.5 39
Tropé et al. 2012 [32] 127 14 18 36 44 50 62 31 12
Vergote et al. 2010 [1, 33] 336 19 64 22 70 60 202 22 20
Winter et al. 2008 [34] 330 8 29 21.7 71 251 76 20
Amstrong IV 2006 210 36 75 64 135 50
Amstrong IP 2006 205 38 78 62 127
Braicu et al. 2011 [36] 415 33.5
Eisenkop et al. 2003 [37] 408 86 351 10 41 4 16
Chi et al. 2009 [38] 210 27 57 52 110 20 43 19
Eisenhauer1 [39] 57 23 13 77 44 0 0 12
Eisenhauer2 [39] 122 30 37 70 85 0 0 7
Chi et al. 2006 [40] 441 15 67 36 169 49 233 65
Chi et al. 2010 [41] 141 30 42 60 85 10 14 22 48
Kobal et al. 2018 [42] 108 54 58 17.6 19 29 31 22 36
Kang et al. 2011 [43] 140 58 81 33.6 47 8.6 12
Kommos 2010 [44] 267 47 126 32.6 87 20 57 33
Magtibay et al. 2006 [45] 66 9 6 32 21 18 12 28 40
Rafii et al. 2012 [46] 180 11
Rodriguez et al. 2013 [47] 4312 20 860 40 1746 39 1647 40
Salani et al. 2007 [48] 102 39 40 47 35
Sperling et al. 2013 [49] 3129 46 1296 54 1502 40
Van Meurs et al. 2013 [50] 336 20
Wimberger et al. 2010 [51] 573 12 29 58
Winter et al. 2007 [52] 1895 23 437 41 791 35 667 40
Zivanovic et al. 2010 [53] 526 18 93 42 221 40 212
Llueca and Escrig 2017 [54] 90 82 74 6 5 14 11 31 39
Total patients 25728
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Fig. 1 Complete cytoreductive surgery (CCS) rate (P-chart). Each dot represents an included study. The gray area (standard zone) is within the
95% confidence interval, the blue area (alert zone) is between the 95% and 99.8% confidence intervals, and the white area (alarm zone) is outside
the 99.8% limit
Fig. 2 Optimal cytoreductive surgery (OCS) rate (P-chart). Each dot represents an included study. The gray area (standard zone) is within the 95%
confidence interval, the blue area (alert zone) is between the 95% and 99.8% confidence intervals, and the white area (alarm zone) is outside of
the 99.8% limit
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The SCS rate was evaluated in 27 series with a total of
7291 patients included. The weighted average SCS was
29% and the quality limit was > 39% (Fig. 3).
Morbidity
Major complications were evaluated in 23 series with a total
of 4519 patients evaluated. The weighted average morbidity
was 23% and the quality limit was > 33% (Fig. 4).
Survival
The 5-year survival rate was evaluated in 19 series with
a total of 5554 patients included. The weighted average
overall survival (OS) was 37% and the quality limit was <
27% (Fig. 5).
Discussion
A QI is a parameter that is used to measure the quality
of medical assistance and provides information on as-
pects that can be improved. To evaluate the quality of a
service or process, comparisons need to be established
with some sort of guide or reference. This reference is
what we define as a standard. Ideally, quality should be
measured for populations with a common health care
system and similar social customs (i.e., those in which
different surgical teams have similar access to resources).
Moreover, any risk-adjusted evaluation of the parameters
involved in measuring quality should be taken into ac-
count for comparisons. In the absence of these ideal
conditions, standards need to be identified in the data
available in the literature, even if this means comparing
systems as different as those in Japan, Europe, or the
USA. This will at least offer a global perspective of what
standards should be considered. Several studies have
demonstrated the importance of hospital volume and
mortality associated with treatments, and they have
made important contributions to our understanding of
the quality of surgical care. However, these parameters
are insufficient [55, 56].
In 2016, the European Society of Gynaecological Oncol-
ogy (ESGO) published an assessment of advanced ovarian
cancer care based on formally developed QIs [9]. In this
report, 10 QIs, including structural factors, clinical care
process, treatment efficacy, and outcomes, were described.
However quality limits where established only in two QIs,
including the rate of complete surgical resection and the
rate of primary debulking surgery. The quality limits were
> 50% for both QIs. There are important methodological
differences between the study by the ESGO and our study.
The most relevant difference between studies is that the
study by the ESGO identified QIs for a variety of factors
based on estimations of a panel of ovarian cancer ex-
perts who were more focused on the accreditation of
reference centers and health planning of ovarian cancer
care. Our study identified outcome QIs and established
AQLs for all items according to worldwide data. We
used a different statistical methodology aimed to con-
trol variability that is inherent in the data of different
institutions. Because these two studies covered different
aspects of quality health care and methodology, they
can be considered complementary.
Fig. 3 Suboptimal cytoreductive surgery (SCS) rate (P-chart). Each dot represents an included study. The gray area (standard zone) is within the
95% confidence interval, the blue area (alert zone) is between the 95% and 99.8% confidence intervals, and the white area (alarm zone) is outside
of the 99.8% limit
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An investigation such as our study has several disad-
vantages when selecting QIs and series. With regard to
QIs, there may be other indicators (e.g., operative time,
blood transfusion, length of hospital stay, and costs).
However, our selection was based on the most fre-
quently published data available to obtain a relevant
volume of series and cases for analysis. We used litera-
ture that was published in English between 2006 and
2018 for selection of the series. From 2005, there has
been worldwide development and progress in this highly
complex AOCS. We believe that our results offer a gen-
eral view of what the clinical indicators should be, as
Fig. 5 Five-year survival rate (P-chart). Each dot represents an included study. The gray area (standard zone) is within the 95% confidence interval,
the blue area (alert zone) is between the 95% and 99.8% confidence intervals, and the white area (alarm zone) is outside of the 99.8% limit
Fig. 4 Morbidity rate (P-chart). Each dot represents an included study. The gray area (standard zone) is within the 95% confidence interval, the
blue area (alert zone) is between the 95% and 99.8% confidence intervals, and the white area (alarm zone) is outside of the 99.8% limit
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well as establishing AQLs that can be considered as
standards.
In our study, standards and AQLs were obtained using
weighted averages and confidence intervals of 99.8% and
95%. Using this method, the probability of a particular
observation being outside such limits is low if the evalu-
ated procedure is under control (i.e., p < 0.002 and p <
0.05). In SPC terminology, such limits establish alarm
(99.8%) or alert (95%) areas. When a result is either
above or below the alarm zone, it may be considered ei-
ther unfavorable or outstanding, depending on the na-
ture of the evaluated variable. For CCS, a result below
the alarm zone limit should be considered a bad out-
come. However, for morbidity, when a result is below
the alarm zone limit, it is considered to be an excellent
result.
The CCS rates reported in the literature are highly
variable, not only between regions, but within the same
region. It is a common phenomenon that depends on
the specialization of the working groups and their multi-
disciplinary organization. In our study, OCS and CCS
quality limits were 71% in AOCS when considered to-
gether. This result is similar to that published recently
by Park et al. where the percentage of OCS and CCS
was 78% in the responses of a survey [57].
In our study, almost all of the graphs showed great
variability of the results of the series that were investi-
gated. This is called statistical overdispersion of the data
[58]. The statistical phenomenon of overdispersion can
be explained by two reasons. First, this phenomenon can
be caused by the different definitions used in the studies,
which may result in a case selection bias. Second, and
much more likely, is that we did not compare similar
practices.
In clinical practice, the FIGO (International Federation
of Gynecology and Obstetrics) system is widely used to
characterize and predict survival in ovarian cancer [59].
Intraperitoneal spread is the most typical presentation of
stages III and IV ovarian cancer. Unfortunately, the
FIGO system fails in characterization of tumor burden
and in describing anatomical regions that are affected.
Patients with stage IIIc ovarian cancer may have local-
ized and easily resectable carcinomatosis, but they may
also have extensive unresectable disease [60]. To object-
ively determine and quantify the tumor burden in these
advanced ovarian cancer stages, some authors have de-
scribed assessment tools in the field of surgical oncology.
One of the most frequently used tool is the Peritoneal
Cancer Index (PCI), which describes peritoneal carcin-
omatosis of all types [61]. Specifically for ovarian cancer,
Fagotty, Allety, and Zivanovic [54] described some other
assessment tools. The PCI provides useful information
about the precise distribution and tumor volume, repre-
senting in detail the extent of peritoneal spread. We
believe that the PCI should be incorporated as a comple-
ment to the FIGO stages for comparison of different
series of different authors in a more objective manner.
This process could decrease the rate of overdispersion of
QIs.
In the same manner, drawing conclusions about mor-
bidity is difficult if we are not speaking the same lan-
guage. The overdispersion phenomenon is also observed
between the lower and the upper quality limits of the
morbidity rate in a P-chart. Recently, we found that
major complications (grades III–IV of Clavien–Dindo)
were much higher with a PCI >20 than those found with
a PCI < 10 [2]. This finding could explain the enormous
variability of data observed for the morbidity rate (Fig.
4). However, the aggressiveness of the tumor and the
tumor biology itself could have some relevant role in this
matter.
OS and progression-free survival (PFS) are important
endpoints for evaluating new anti-cancer therapies. Al-
though OS is considered to be the most clinically rele-
vant endpoint in ovarian cancer treatment, it is affected
by use of multiple post-progression therapies. Addition-
ally, the time required to evaluate OS is often consider-
able. PFS, which measures the time to disease
progression or death after treatment, is a useful endpoint
because it can show a clinical benefit and is more rapidly
assessable than OS [62]. Although the use of PFS is in-
creasing considerably, most authors still refer to OS as a
reference value. There are many factors that influence
OS. In our study, the average 5-year OS rate was 37%,
and there was a large amount of variability (Fig. 5). As
previously reported, the OS rate can rise to > 50% with a
PCI < 10 and the inverse situation occurs with a PCI >
20 [63, 64].
This study has several limitations. First, this was a
narrative retrospective review that combined data from
clinical trials and retrospective institutional cohorts.
Therefore, conclusions must be drawn with caution.
Second, extracting data from the published series was
difficult because of the enormous variability of the var-
iables and the concepts included in the series. There-
fore, there may have been some interpretation bias.
Variability is inherent to any process, although beyond
a certain variability, it becomes excessive. The key
point to dealing with variability is delimiting and dis-
tinguishing normal and undesirable variability. The
method used in this study allowed us to define the
interval that discriminates variability from dispersion
of data.
In conclusion, for advanced ovarian cancer surgery,
five QIs were identified, the rates of CCS, OCS, SCS,
complications and overall 5-year survival with AQLs of
< 27%, < 23%, > 39%, > 33%, and < 27%, respectively.
For most physicians and surgeons, quality indicates good
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clinical outcomes and the effectiveness of treatment or
surgery. In the clinical setting, quality should be mea-
sured according to objective clinical indicators, which
was the goal of our study. Specific values that define
quality standards in AOCS are essential.
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